This is what I was able to find on Transarterial Chemoembolization (TACE):
TACE involves mixing cytotoxic agents such as doxorubicin, cisplatin, mitomycin C with lipiodol and administering it into the feeding artery of the tumor. This is followed by transarterial embolization to block blood flow to the supplying artery. Lipiodol selectively remains more in tumor nodules for several weeks to over a year. TACE thus has both selective ischemic and therapeutic effects on HCC; the embolotherapy interrupts the arterial blood flow to the tumor inducing its ischemic necrosis, and
prevents washout of the administered chemotherapeutic agents which will remain in the tumor for a longer period at a higher concentration. It is thus believed that the combination of embolotherapy and
regional chemotherapy has synergetic, antitumor effects with lower systemic drug levels, less toxicity, and minimal damage to liver (Lau 2008, Shin 2009).
You can read this page for more info http://www.ghc.org/all-sites/clinical/criteria/pdf/transarterial_chemoembolization_liver_tumors.pdf;jsessionid=TPUYQKEYDIX5DJCISQ3SHPQ
Comment Reply
Shiva,
This is what I was able to find on Transarterial Chemoembolization (TACE):
TACE involves mixing cytotoxic agents such as doxorubicin, cisplatin, mitomycin C with lipiodol and administering it into the feeding artery of the tumor. This is followed by transarterial embolization to block blood flow to the supplying artery. Lipiodol selectively remains more in tumor nodules for several weeks to over a year. TACE thus has both selective ischemic and therapeutic effects on HCC; the embolotherapy interrupts the arterial blood flow to the tumor inducing its ischemic necrosis, and
prevents washout of the administered chemotherapeutic agents which will remain in the tumor for a longer period at a higher concentration. It is thus believed that the combination of embolotherapy and
regional chemotherapy has synergetic, antitumor effects with lower systemic drug levels, less toxicity, and minimal damage to liver (Lau 2008, Shin 2009).
You can read this page for more info http://www.ghc.org/all-sites/clinical/criteria/pdf/transarterial_chemoembolization_liver_tumors.pdf;jsessionid=TPUYQKEYDIX5DJCISQ3SHPQ
February 22, 2011 - 6:55amThis Comment
Reply